CRISPR Therapeutics AG (CRSP) Accounts Payables (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Accounts Payables data on file, last reported at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 4.46% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $13.6 million (up 4.46% YoY), and the FY2025 full-year result was $11.1 million, down 24.28% from the prior year.
• Accounts Payables grew to $13.6 million in Q1 2026, from $11.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $45.2 million in Q1 2023 to a low of $9.5 million in Q2 2024.
• A 5-year average of $21.4 million and a median of $16.5 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 215.87% in 2022 and slumped 65.74% in 2024, its largest moves.
• Tracing CRSP's Accounts Payables over 5 years: stood at $27.4 million in 2022, then soared by 39.08% to $38.1 million in 2023, then sank by 61.44% to $14.7 million in 2024, then decreased by 24.28% to $11.1 million in 2025, then increased by 22.53% to $13.6 million in 2026.
• Business Quant data shows CRSP's Accounts Payables at $13.6 million in Q1 2026, $11.1 million in Q4 2025, and $11.8 million in Q3 2025.